Background: Glaucoma is a chronic and progressive condition characterized by degeneration of the optic nerve, which can be differentiated from other types of acquired optic neuropathy by the distinctive morphology of the optic nerve head. Hence; the present study was conducted for assessing the efficacy of Dorzolamide 2 percent timolol 0.5 percent fixed combination therapy in patients of primary open angle glaucoma. Materials & methods: A total of 20 patients of POAG were enrolled. Patients fulfilling the inclusion criteria and having none of the exclusion criteria were enrolled in the study after obtaining written informed consent. The data obtained was compiled on a proforma and appropriate tests will thus be applied.Fixed drug combination of Dorzolamide2%/ Timolol 0.5% (DTFC) dosed twice daily. Patients was then be called for follow up at 2ndweek, 4thweek and 6thweek during the study period and IOP was recorded. In both the groups, the eye that was affected was considered as the study eye.IOP readings were taken from the study eye with the Goldmann applanation tonometer (GAT) at each visit.All the results were analyzed by SPSS software. Results: Mean age of the patients was 61.3 years. 60 percent of the patients were males while the remaining were females. Mean IOP at baseline, at visit 1, visit 2, visit 3 and visit 4 was 29.7, 28.9, 19.1, 15.9 and 14.2 respectively. Significant results were obtained while comparing the mean IOP at different time intervals. Conjunctival hyperemia, eye irritation and taste perversion were seen in 20 percent, 5 percent and 5 percent of the patients respectively. Conclusion: Dorzolamide/timolol represents a well-tolerated and efficacious fixed combination therapy for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma. This formulation is particularly beneficial for individuals who do not achieve sufficient control with first-line monotherapy.